



We are Daiichi Sankyo.

We care for every heartbeat. Our lives are full of precious moments and every one of them matters. The key is to not miss them and treasure them in our hearts. We at Daiichi Sankyo share this same feeling. That's why we are committed to provide innovative cardiovascular therapeutic options for our patients. At some point in our lives, all of us will know someone who has been affected by cardiovascular disease. It remains Europe's leading cause of death, responsible for more than 10,000 deaths every day.¹

Our goal is to protect people from cardiovascular disease and help those who suffer from it. We focus on supporting the clinical community and healthcare ecosystems across Europe to ensure that we are able to help those who are affected by cardiovascular disease today. Beyond providing medicines, we investigate new opportunities to improve care through patient-centric approaches, new technologies and partnerships. We believe that healthcare can only be improved by bringing together like-minded, caring groups and individuals, who share our passion and commitment to protecting lives. We want people to get the best out of every moment because each one of them is a gift.

We have every single moment at heart. Just like you do.

Our purpose

To contribute to the enrichment of quality of life around the world.

Our mission

To create innovative pharmaceuticals addressing diverse medical needs.

Our vision

To become an innovative global healthcare company contributing to the sustainable development of society.

Visit our website for more information:
www.daiichi-sankyo.eu



Passion for Innovation.
Compassion for Patients.™

¹ ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020; 41(1): 111-188.


Our disease areas

We are experts in the treatment of cardiovascular disease and have a long history in bringing needed therapies to patients. Our broad portfolio of innovative medicines adheres to the highest standards, and we work tirelessly to remain a trusted partner to both healthcare professionals and the patient communities that we serve. We put the patient at the heart of everything we do, seek to improve access to innovative treatments and empower patients to better manage their conditions in partnership with healthcare professionals.



¹ Daiichi Sankyo. Company presentation. Data on file.

We are a global pharmaceutical company with over 120 years of scientific expertise



- 1900**
First isolation of adrenaline by Dr. Jokichi Takamine, the first president of Sankyo Shoten
- 1973**
Discovery of the first HMG-CoA reductase inhibitor by Sankyo - origin of the statin class
- 1985**
Daiichi discovers levofloxacin, the first third-generation quinolone
- 1989**
Launch of olmesartan, an angiotensin II receptor blocker

Medicines in our portfolio:

- Adrenalin**
an adrenal cortex hormone that became the first blockbuster medicine of the 20th century
- Edoxaban**
an anticoagulant and direct factor Xa inhibitor
- Pravastatin**
an anti-hyperlipidemic agent

- 2015**
Launch of edoxaban, a non-vitamin K antagonist oral anticoagulant (NOAC) and direct factor Xa inhibitor
- 2020**
European Commission approval and first launch of bempedoic acid in Europe. Bempedoic acid and its fixed-dose combination with ezetimibe is approved for use in adults with primary hypercholesterolaemia or mixed dyslipidaemia in Europe²

We have a long history in bringing cardiovascular therapies to patients



Passion for Innovation.
Compassion for Patients.™

Date of revision 07/2022

¹ As of March 31, 2022 | Exchange rate: 130,56 Yen/EUR (Annual average)
Source: Financial Highlights – Daiichi Sankyo https://www.daiichisankyo.com/investors/financial_highlights

² Bempedoic acid / the combination of bempedoic acid with ezetimibe was approved by the EMA in April 2020 with a first market launch in late 2020.